Key result
Second-generation ASIs reduce SBP vs placebo but increase hyperkalemia, hyponatremia, and hypotension.
Why the study?
Second-generation aldosterone-synthase inhibitors may offer a novel treatment for hypertension, but their efficacy and safety require assessment.
Do second-generation aldosterone-synthase inhibitors reduce systolic blood pressure in patients with hypertension?
Meta-Analysis
Do second-generation aldosterone-synthase inhibitors reduce systolic blood pressure in patients with hypertension?
Second-generation aldosterone-synthase inhibitors have a high probability of providing clinically significant systolic blood pressure reduction in hypertension, though they are associated with increased risks of hyperkalemia, hyponatremia, and hypotension.
Requires careful monitoring for adverse effects; extends BP-lowering efficacy of second-generation ASIs but leaves net clinical benefit open.
BACKGROUND: Second-generation aldosterone-synthase inhibitors (ASIs) may offer a novel treatment for hypertension. OBJECTIVES: The objective of the study was to assess the efficacy and safety of ASIs in this clinical setting. METHODS: We searched major databases for randomized controlled trials (RCTs) assessing ASIs (baxdrostat, lorundrostat, and vicadrostat) in patients with hypertension. For efficacy outcomes, mean differences (MD) with 95% credible intervals (CrIs) were estimated using a Bayesian random-effects model. For adverse events, OR with 95% CrI were estimated using a Bayesian binomial-normal hierarchical model. The protocol was registered in Prospective Register of Systematic Reviews (CRD420251132306). RESULTS: 0.1). In subgroup analysis, the probability of achieving a clinically meaningful reduction in SBP (MD < -5 mm Hg) was 87.5% with baxdrostat and 94.3% with lorundrostat. CONCLUSIONS: Second-generation ASIs had a high likelihood of a clinically significant reduction in SBP compared with placebo. However, hyperkalemia, hyponatremia, and hypotension were more frequent with ASIs.
No takes yet. Share an insight, caveat, or question.
Queiroga et al. (2026) conducted a meta-analysis in hypertension. Second-generation aldosterone-synthase inhibitors (ASIs) vs. placebo was evaluated on reduction in systolic blood pressure (SBP). Second-generation ASIs had a high likelihood of a clinically significant reduction in SBP compared with placebo, but hyperkalemia, hyponatremia, and hypotension were more frequent.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: